paz320
Small moleculeexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Mar 1, 2011 (NCT02060916)
Timeline
2010s
- Jan 1, 2011
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Neutral alpha-glucosidase ABINHIBITOR
GANAB inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- paz320
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04569214 | Phase 2 | Sep 30, 2012 | Boston Therapeutics, Centre Hospitalier Robert Bisson |
| NCT02060916 | Phase 2 | Mar 1, 2011 | Boston Therapeutics, Dartmouth University |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Boston Therapeutics | For profit | 2 | 2 | 1 | 2011 |
| Centre Hospitalier Robert Bisson | Academic/Hospital | 1 | 0 | 1 | 2012 |
| Dartmouth University | Academic/Hospital | 1 | 0 | 1 | 2011 |
3 organizations
Page 1 / 1